The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy

NCT00983034 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2009-09-23

No results posted yet for this study

Summary

Membranous nephropathy (MN) may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori (H. pylori) antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.

Conditions

Interventions

DRUG

lansoprazole, amoxicillin, clarithromycin

lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Yasar Caliskan, MD · Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University

  • Berna Yelken, MD · Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University

  • Halil Yazici, MD · Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University

  • Mehmet S Sever, Prof MD · Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-12-31
Completion
2009-07-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00983034 on ClinicalTrials.gov